organization · Reporting owner
Proehl Investment Ventures LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dermata Therapeutics, Inc.DRMA · Entity 8182 | 10% owner | August 17, 2021 | August 17, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dermata Therapeutics, Inc.
Report date August 17, 2021 · Filed August 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,905,544 |
Ending reported balance
After 2021-08-17 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2021-08-17 · Conversion · Acquired 361,147 · Balance 1,278,464 F1: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date. Row 2 · 2021-08-17 · Conversion · Acquired 111,951 · Balance 1,390,415 F2: The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date. Row 3 · 2021-08-17 · Conversion · Acquired 181,585 · Balance 1,572,000 F3: The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date. Row 4 · 2021-08-17 · Conversion · Acquired 1,247,904 · Balance 2,819,904 F4: The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date. Row 5 · 2021-08-17 · Conversion · Acquired 85,640 · Balance 2,905,544 F5: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date. |
| Series 1d Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-08-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-08-17 · Conversion · Disposed 2,436,657 · Balance 0 F1: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date. |
| Series 1a Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-08-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-08-17 · Conversion · Disposed 2,295,000 · Balance 0 F2: The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date. |
| Series 1b Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-08-17 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-08-17 · Conversion · Disposed 3,722,500 · Balance 0 F3: The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date. |
| Series 1c Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-08-17 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-08-17 · Conversion · Disposed 25,582,050 · Balance 0 F4: The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date. |
| Series 1 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-08-17 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-08-17 · Conversion · Disposed 1,755,622 · Balance 0 F5: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date. |
| Series 1a WarrantsSEC Table II · derivative / convertible security · Expires 2026-03-14 | Direct | 0 |
Reported balance
After 2021-08-17 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-08-17 · Conversion · Disposed 573,750 · Balance 0 F6: The Series 1a Preferred Warrants converted into warrants to purchase Common Stock in connection with the IPO. |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $20.50 · Expires 2026-03-14 | Direct | 27,987 |
Reported balance
After 2021-08-17 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2021-08-17 · Conversion · Acquired 27,987 · Balance 27,987 |
Filing footnotes · ownership attribution and instrument terms
F1: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date.
F2: The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date.
F3: The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date.
F4: The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date.
F5: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date.
F6: The Series 1a Preferred Warrants converted into warrants to purchase Common Stock in connection with the IPO.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2021 Filed Aug 17, 2021 12:48 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionWarrant to Purchase Common Stock · Derivative | 27,987 | $0.00 Strike: $20.50 | $0.00 |
DisclosureSEC source: 0000905718-21-001108 · dermata_fm4aug172021.xml · derivative · entry 12 Proehl Investment Ventures LLC · CIK 0001877913 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,987 Underlying: Common Stock · 27,987 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 12:48 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionSeries 1a Warrants · Derivative | 573,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001108 · dermata_fm4aug172021.xml · derivative · entry 11 Proehl Investment Ventures LLC · CIK 0001877913 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,987 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: The Series 1a Preferred Warrants converted into warrants to purchase Common Stock in connection with the IPO. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 12:48 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionSeries 1 Preferred Stock · Derivative | 1,755,622 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001108 · dermata_fm4aug172021.xml · derivative · entry 10 Proehl Investment Ventures LLC · CIK 0001877913 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 85,640 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date. F5 · derivative.exercise_date: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date. F5 · derivative.expiration_date: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 12:48 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionSeries 1c Preferred Stock · Derivative | 25,582,050 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001108 · dermata_fm4aug172021.xml · derivative · entry 9 Proehl Investment Ventures LLC · CIK 0001877913 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,247,904 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date. F4 · derivative.exercise_date: The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date. F4 · derivative.expiration_date: The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 12:48 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionSeries 1b Preferred Stock · Derivative | 3,722,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001108 · dermata_fm4aug172021.xml · derivative · entry 8 Proehl Investment Ventures LLC · CIK 0001877913 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 181,585 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date. F3 · derivative.exercise_date: The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date. F3 · derivative.expiration_date: The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 12:48 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionSeries 1a Preferred Stock · Derivative | 2,295,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001108 · dermata_fm4aug172021.xml · derivative · entry 7 Proehl Investment Ventures LLC · CIK 0001877913 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 111,951 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date. F2 · derivative.exercise_date: The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date. F2 · derivative.expiration_date: The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 12:48 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionSeries 1d Preferred Stock · Derivative | 2,436,657 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-001108 · dermata_fm4aug172021.xml · derivative · entry 6 Proehl Investment Ventures LLC · CIK 0001877913 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 361,147 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date. F1 · derivative.exercise_date: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date. F1 · derivative.expiration_date: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 12:48 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionCommon Stock | 85,640 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-21-001108 · dermata_fm4aug172021.xml · nonDerivative · entry 5 Proehl Investment Ventures LLC · CIK 0001877913 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,905,544 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 12:48 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionCommon Stock | 1,247,904 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-21-001108 · dermata_fm4aug172021.xml · nonDerivative · entry 4 Proehl Investment Ventures LLC · CIK 0001877913 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,819,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 12:48 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionCommon Stock | 181,585 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-21-001108 · dermata_fm4aug172021.xml · nonDerivative · entry 3 Proehl Investment Ventures LLC · CIK 0001877913 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,572,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 12:48 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionCommon Stock | 111,951 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-21-001108 · dermata_fm4aug172021.xml · nonDerivative · entry 2 Proehl Investment Ventures LLC · CIK 0001877913 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,390,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date. Read SEC document |
| August 17, 2021 Filed Aug 17, 2021 12:48 UTC | Dermata Therapeutics, Inc. DRMA · Entity 8182 | ConversionCommon Stock | 361,147 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905718-21-001108 · dermata_fm4aug172021.xml · nonDerivative · entry 1 Proehl Investment Ventures LLC · CIK 0001877913 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,278,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.